Therapeutic monoclonal antibodies for COVID-19 management: an update

References

• Chavda VP, Patel AB, Vihol D, et al. Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update. Clin Compl Med Pharmacol. 2022;2(1):100021.
   Google Scholar
• Chavda VP, Kapadia C, Soni S, et al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. 2022 Feb 21;145:351–371. DOI:10.2217/imt-2021–0168
   PubMed Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O’Neill N, et al. World health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Feehan J, Apostolopoulos V. A veterinary vaccine for SARS-CoV-2: the first COVID-19 vaccine for animals. Vaccines (Basel). 2021;9(6):631.
   PubMed Web of Science ®Google Scholar
• WHO. WHO COVID-19 Dashboard. 2021 [cited 2021 5 11 2022]. https://covid19.who.int/
   Google Scholar
• Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev Vaccines. 2022 Feb;19:null–null. DOI:10.1080/14760584.2022.2044800
   Google Scholar
• Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr Res Pharmacol Drug Discovery. 2022 3;100086.
   PubMedGoogle Scholar
• Díez J-M, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020;12(8):571–576.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102.
   PubMed Web of Science ®Google Scholar
• Shao Z, Feng Y, Zhong L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunology. 2020;9(10):e1192.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Vora LK, Pandya AK, et al. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619–2636.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: towards third generation vaccination era. Expert Rev Vaccines. 2021 Sep;20(12):1549–1560.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Apostolopoulos VM. An opportunistic infection in the aged immunocompromised individual: a reason for concern in COVID-19. Maturitas. 2021;154:58–61.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Gajjar N, Shah N, et al. Darunavir ethanolate: repurposing an anti-HIV drug in COVID-19 treatment. Eur J Med Chem Rep. 2021;3:100013.
   PubMedGoogle Scholar
• Xiaojie S, Yu L, lei Y, et al. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2021;50:102125.
   Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184(7):1804–1820.e16.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393.
   PubMed Web of Science ®Google Scholar
• Alape-Girón A, Moreira-Soto A, Arguedas M, et al. Heterologous hyperimmune polyclonal antibodies against SARS-CoV-2: a broad coverage, affordable, and scalable potential immunotherapy for COVID-19. Front Med (Lausanne). 2021;8:743325.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol. 2022;94(7):2986–3005.
   PubMed Web of Science ®Google Scholar
• Lloyd EC, Gandhi TN, Petty LA. Monoclonal antibodies for COVID-19. JAMA. 2021;325(10):1015.
   PubMedGoogle Scholar
• Redwan EM. COVID-19 pandemic and vaccination build herd immunity. Eur Rev Med Pharmacol Sci. 2021;25(2):577–579.
   PubMed Web of Science ®Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589.
   PubMed Web of Science ®Google Scholar
• Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. Lancet Public Health. 2020;5(4):e186–e187.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452.
   PubMed Web of Science ®Google Scholar
• Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. Radiology. 2020;295(1):16–17.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, KK-W T, Tse H, et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544–555.
   PubMed Web of Science ®Google Scholar
• Pal M, Berhanu G, Desalegn C, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020. DOI:10.7759/cureus.7423
   Web of Science ®Google Scholar
• Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. J Dig Endosc. 2020;11(1):3–7.
   Web of Science ®Google Scholar
• Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–460.
   PubMed Web of Science ®Google Scholar
• Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China. Eurosurveillance. 2020;25(5):2000062.
   Web of Science ®Google Scholar
• Linton NM, Kobayashi T, Yang Y, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J Clin Med. 2020;9(2):538.
   PubMed Web of Science ®Google Scholar
• Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 2020;159(1):81–95.
   PubMed Web of Science ®Google Scholar
• Liu DX, Liang JQ, Fung TS. Human coronavirus-229E -OC43, -NL63, and -HKU1. In: DH CB, Zuckerman M, editors. Encyclopedia of virology (Elsevier). 2021. p. 428–440. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204879/ 12 01 2022
   Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines. 2021;20(12):1549–1560.
   PubMed Web of Science ®Google Scholar
• Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antiviral Res. 2018;149:58–74.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Kok K-H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236.
   PubMed Web of Science ®Google Scholar
• Ellis R. WHO says Indian COVID strain ‘a variant of concern.’ 2021 [cited 2022 Feb 22]. https://www.webmd.com/lung/news/20210510/who-says-indian-covid-strain-a-variant-of-concern
   Google Scholar
• Chavda VP, Hossain MK, Beladiya J, et al. Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics. 2021;1(3):337–356.
   Google Scholar
• Variant Technical Group (UK Health Security Agency). SARS-CoV-2 variants of concern and variants under investigation in England. 2021 25 01 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036501/Technical_Briefing_29_published_26_November_2021.pdf
   Google Scholar
• Ferreira I, Datir R, Papa G SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies , et al. mBio. bioRxiv. 2021.05.08.443253 2021. DOI:10.1101/2021.05.08.443253
   Google Scholar
• Chavda VP, Bezbaruah R, Athalye M, et al. Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena. Viruses. 2022;14(4):759.
   PubMed Web of Science ®Google Scholar
• Division of Viral Diseases. SARS-CoV-2 variant classifications and definitions. CDC science, national center for immunization and respiratory diseases (NCIRD), Division of Viral Diseases. 2021 [cited 2021 May 23]. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
   Google Scholar
• Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27(11):2025–2031.
   PubMed Web of Science ®Google Scholar
• Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184(16):4220–4236.e13.
   PubMed Web of Science ®Google Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv : the Preprint Server for Health Sciences. 2021. DOI:10.1101/2021.03.07.21252647
   Google Scholar
• Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. USFDA. 2021 [cited 2021 Dec 22]. https://www.fda.gov/media/145802/download
   Google Scholar
• US FDA. casirivimab with imdevimab - USFDA Factsheet. fda.gov. 2021 [cited 2022 Feb 22]. https://www.fda.gov/media/145612/download
   Google Scholar
• Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126–2128.
   PubMed Web of Science ®Google Scholar
• Diseases TLI. Emerging SARS-CoV-2 variants: shooting the messenger. Lancet Infect Dis. 2021 Dec 12;10(1016/S1473–3099(21)00770–2). DOI:10.1016/S1473-3099(21)00770-2
   Google Scholar
• Chavda VP, Apostolopoulos V. Is booster dose strategy sufficient for omicron variant of SARS-CoV-2? Vaccines (Basel). 2022;10(3):367.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Apostolopoulos V. Omicron variant (B.1.1.529) of SARS-CoV-2: threat for the elderly? Maturitas. 2022 Feb 8;158:78–81.
   PubMed Web of Science ®Google Scholar
• Eyawo O, Viens AM. Rethinking the central role of equity in the global governance of pandemic response. J Bioeth Inq. 2020;17(4):549–553.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Vora LK, Vihol DR. COVAX-19Ⓡ vaccine: completely blocks virus transmission to non-immune individuals. Clin Compl Med Pharmacol. 2021;1(1):100004.
   Google Scholar
• Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in Southern Africa. Nature. 2022;10.1038/s41586-022-04411–y. DOI:10.1038/s41586-022-04411-y
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells. Proc Natl Acad Sci U S A. 2020;117(13):7001–7003.
   PubMed Web of Science ®Google Scholar
• Thunders M, Delahunt B. Gene of the month: TMPRSS2 (transmembrane serine protease 2). J Clin Pathol. 2020;73(12):773–776.
   PubMed Web of Science ®Google Scholar
• Kaur N, Singh R, Dar Z, et al. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. Infect Genet Evol. 2021;89:104490.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):1–8.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun W, Li J, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv. 2020;20024166. DOI:10.1101/2020.02.17.20024166. 2020 February 17.
   Google Scholar
• Perlman AD S. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927.
   PubMed Web of Science ®Google Scholar
• Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020;20(5):277.
   PubMedGoogle Scholar
• Tan L. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33.
   PubMed Web of Science ®Google Scholar
• Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–270.
   PubMed Web of Science ®Google Scholar
• Li D. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study. Signal Transduct Target Ther. 2020;5(1):62.
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Liu J, et al. EBioMedicine WL-, 2020 U. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinl Infect Dis. 2020;71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. 2020;20035048. DOI:10.1101/2020.03.12.20035048. 2020 March 12.
   Web of Science ®Google Scholar
• Liu J, Li S, Liu J. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Chen N. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
   PubMed Web of Science ®Google Scholar
• Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020;1–5. DOI:10.1101/2020.02.10.20021832
   Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
   PubMed Web of Science ®Google Scholar
• Nicol T. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG biotech). J Clin Virol. 2020;129:104511.
   PubMed Web of Science ®Google Scholar
• de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12(1):75.
   PubMed Web of Science ®Google Scholar
• Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.
   PubMed Web of Science ®Google Scholar
• Sardu C, Maggi P, Messina V, et al. Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with covid-19 infection? Data from centers of southern Italy. J Am Heart Assoc. 2020;9(17). DOI:10.1161/JAHA.120.016948
   PubMed Web of Science ®Google Scholar
• Daniels LB, Ren J, Kumar K, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American heart association’s COVID-19 cardiovascular disease registry. PLOS ONE. 2021;16(7):e0254635.
   PubMed Web of Science ®Google Scholar
• Berbudi A, Rahmadika N, Tjahjadi AI, et al. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442–449.
   PubMed Web of Science ®Google Scholar
• Landstra CP, de Koning EJP. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol (Lausanne). 2021;12(June):1–18.
   Google Scholar
• Sardu C, Gargiulo G, Esposito G, et al. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc Diabetol. 2020;19(1):76.
   PubMed Web of Science ®Google Scholar
• Balmeh N, Mahmoudi S, Mohammadi N, et al. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inf Med Unlocked. 2020;20:100407.
   PubMedGoogle Scholar
• Huang Y, Yang C, feng XX, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–1149.
   PubMed Web of Science ®Google Scholar
• Azimi A. TMPRSS2 inhibitors, bromhexine, aprotinin, camostat and nafamostat as potential treatments for COVID-19. Frenxiv. 2020;19 May 2020. DOI:10.31226/osf.io/a3rvm.
   Google Scholar
• Burkert FR, Lanser L. Coronavirus Disease 2019: Clinics, Treatment, and Prevention. Front Microbiol. 2021;12:761887. DOI:10.3389/fmicb.2021.761887.
   PubMed Web of Science ®Google Scholar
• Padhi A, Seal A, Tripathi T. How does arbidol inhibit the novel coronavirus SARS-CoV-2? atomistic insights from molecular dynamics simulations. Biol Med Chem. 2020;2:10.26434/chemrxiv.12464576.v1. DOI:10.26434/chemrxiv.12464576
   Google Scholar
• Saxena A. Drug targets for COVID-19 therapeutics: ongoing global efforts. J Biosci. 2020;45(1). DOI:10.1007/s12038-020-00067-w
   Web of Science ®Google Scholar
• Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–283.
   PubMed Web of Science ®Google Scholar
• Wondmkun YT, Mohammed OA. A review on novel drug targets and future directions for COVID-19 treatment. Biol targ ther. 2020;14:77–82.
   Web of Science ®Google Scholar
• Alexpandi R, De Mesquita JF, Pandian SK, et al. Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. Front Microbiol. 2020;11(2020):1–21.
   PubMedGoogle Scholar
• Nur SM, Hasan MA, Amin M, et al. Design of potential RNAi (miRNA and siRNA) molecules for middle east respiratory syndrome coronavirus (MERS-CoV) gene silencing by computational method. Interdiscip Sci. 2015;7(3):257–265.
   PubMed Web of Science ®Google Scholar
• Silva Júnior Ml de M, de SLMA, Remc D, et al. Review on therapeutic targets for COVID-19: insights from cytokine storm. Postgraduate Medical Journal.2020;1–27. DOI: 10.1136/postgradmedj-2020-138791.
   Web of Science ®Google Scholar
• Hashizume M. Outlook of IL-6 signaling blockade for COVID-19 pneumonia. Inflamm Regen. 2020;40(1):1–34.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Balkrishna A, Thakur P, Singh S, et al. Glucose antimetabolite 2-Deoxy-D-Glucose and its derivative as promising candidates for tackling COVID-19: insights derived from in silico docking and molecular simulations. Authorea. 2020;1–15. DOI:10.22541/au.158567174.40895611
   Google Scholar
• Krumm ZA, Lloyd GM, Francis CP, et al. Precision therapeutic targets for COVID-19. Virol J. 2021;18(1):66.
   PubMed Web of Science ®Google Scholar
• Kifle ZD, Ayele AG, Enyew EF. Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. J Environ Public Health. 2021;2021:6631721. DOI:10.1155/2021/6631721.
   PubMed Web of Science ®Google Scholar
• An EUA for sotrovimab for treatment of COVID-19. Med Lett Drugs Ther. 2021;63(1627):97–xx98. Available from: https://pubmed.ncbi.nlm.nih.gov/34181630/
   PubMed Web of Science ®Google Scholar
• An EUA for bamlanivimab and etesevimab for COVID-19. Med Lett Drugs Ther. 2021;63(1621):49–50. Available from: https://pubmed.ncbi.nlm.nih.gov/34181630/
   PubMed Web of Science ®Google Scholar
• An EUA for casirivimab and imdevimab for COVID-19. Med Lett Drugs Ther. 2020;62(1614):201–202. Available from: https://pubmed.ncbi.nlm.nih.gov/34181630/
   PubMed Web of Science ®Google Scholar
• Anderson TS, O’Donoghue AL, Dechen T, et al. Uptake of outpatient monoclonal antibody treatments for COVID-19 in the United States: a cross-sectional analysis. J Gen Intern Med. 2021;36(12):3922–3924.
   PubMed Web of Science ®Google Scholar
• Boggiano C, Eisinger RW, Lerner AM, et al. Update on and future directions for use of anti-SARS-CoV-2. Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. Annals of Internal Medicine. Nov 2021. DOI:10.7326/M21-3669
   Google Scholar
• Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021;374:n2231.
   PubMedGoogle Scholar
• Hwang Y-C, R-M L, S-C S, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Joyner MJ, Pirofski L-A. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest. 2020;130(10):5112–5114.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski L-A, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio. 2021;12(2). DOI:10.1128/mBio.03372-20
   Web of Science ®Google Scholar
• Yamin R, Jones AT, Hoffmann -H-H, et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature. 2021;599(7885):465–470.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Wang TT, Dahan R, et al. Signaling by antibodies: recent progress. Annu Rev Immunol. 2017;35(1):285–311.
   PubMedGoogle Scholar
• Branstetter E, Duff RJ, Kuhns S, et al. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity. FEBS Open Bio. 2021;11(11):2943–2949.
   PubMed Web of Science ®Google Scholar
• Tang J, Lee Y, Ravichandran S, et al. Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. iScience. 2021;24(9):103006.
   PubMed Web of Science ®Google Scholar
• Hastie KM, Li H, Bedinger D, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science. 2021;374(6566):472–478.
   PubMed Web of Science ®Google Scholar
• Flemming A. Epitope mapping of spike identifies variant-resistant antibodies. Nat Rev Immunol. 2021;21(11):693.
   Google Scholar
• Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–726.
   PubMed Web of Science ®Google Scholar
• Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. 2021;184(15):3949–3961.e11.
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Valoriani B, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther. 2021;10(4):2479–2488.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Fact sheet for health care providers: emergency use authorization for evusheld (tixagevimab co-packaged with cilgavimab). cited February 22, 2022. https://bit.ly/3IWpQjg
   Google Scholar
• Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA. 2022;327(4):384–385.
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N Engl J Med. 2022;386(10):995–998.
   PubMed Web of Science ®Google Scholar
• EMA. EMA recommends use of Celltrion’s regdanvimab for covid-19 treatment. 2021 [cited Feb 25 2022]. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19
   Google Scholar
• Lee JY, Lee JY, Ko J-H, et al. Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease. Front Immunol. 2021:12. [cited 25 Feb 2022]. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2021.772320
   Web of Science ®Google Scholar
• Syed YY. Regdanvimab: first approval. Drugs. 2021;81(18):2133–2137.
   PubMed Web of Science ®Google Scholar
• GSK and vir biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19. GSK. 2021. [cited 25 Feb 2022]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-the-start-of-the-ema-rolling-review-of-vir-7831-sotrovimab-for-the-early-treatment-of-covid-19/
   Google Scholar
• Dolgin E. “Super-antibodies” could curb COVID-19 and help avert future pandemics. Nat Biotechnol. 2021;39(7):783–785.
   PubMed Web of Science ®Google Scholar
• GSK. GSK and vir biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19 - Google search. Press Release. 2021 [cited 2022 Feb 22]. https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-the-start-of-the-ema-rolling-review-of-vir-7831-sotrovimab-for-the-early-treatment-of-covid-19/
   Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2021;185(3):447–456.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu W, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Therap. 2020;3(3):205–212.
   PubMedGoogle Scholar
• Yinjuan L, Lu Q, Haihong B, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: a randomized, double-blind, placebo-controlled, phase I study. Antimicrob Agents Chemother. 2021;65(11):e01063–21.
   PubMed Web of Science ®Google Scholar
• Flaherty L. Department of health and human services. J Emerg Nurs. 2000;26(3):242–246.
   Google Scholar
• Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Engl J Med. 2021 July;14:38515 DOI:10.1056/NEJMoa2102685
   PubMed Web of Science ®Google Scholar
• Kovacech B, Fialova L, Filipcik P, et al. Monoclonal antibodies targeting two immunodominant epitopes on the spike protein neutralize emerging SARS-CoV-2 variants of concern. eBioMedicine. 2022;76:103818.
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–1014.
   PubMed Web of Science ®Google Scholar
• Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv. 2021 December 07;21267432. http://medrxiv.org/content/early/2021/12/13/2021.12.07.21267432.abstract
   Google Scholar
• Zhao S, Zhang H, Yang X, et al. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. Nat Commun. 2021;12(1):4887.
   PubMed Web of Science ®Google Scholar
• Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168–180.
   PubMed Web of Science ®Google Scholar
• Dey G. An overview of drug repurposing: review article. J Med Sci Clin Res. 2019;7(2):3–5.
   Google Scholar
• WHO. Repurposed antiviral drugs for covid-19 — interim WHO solidarity trial results. N Engl J Med. 2020;384(6): 497–511.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Nat Acad Sci. 2020;117(20):10970–10975.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41–51.
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux P-L, et al., Group C-19 C. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32–40.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516.
   PubMed Web of Science ®Google Scholar
• Mariette X, Hermine O, Tharaux P-L, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med. 2021 May;181(9):1241.
   PubMed Web of Science ®Google Scholar
• Marfella R, Paolisso P, Sardu C, et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020;46(5):403–405.
   PubMed Web of Science ®Google Scholar
• Muramatsu K-I, Ishikawa K, Komatsu A, et al. Severe COVID-19 pneumonia treated by intensive immune suppression therapy with a combination of steroid pulse and tocilizumab followed by a tapering dose of steroid therapy during the Delta (B.1.617.2) variant outbreak: a successfully treated case. Cureus. 2021;13(11):e19340.
   PubMed Web of Science ®Google Scholar
• Anti-IL-6R levilimab registered as COVID-19 treatment in Russia. Antibody Society.
   Google Scholar
• Lomakin NV, Bakirov BA, Protsenko DN, et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III Corona clinical study. Inflamm Res. 2021;70(10–12):1233–1246.
   PubMed Web of Science ®Google Scholar
• Emadi A, Chua JV, Talwani R, et al. Safety and efficacy of imatinib for hospitalized adults with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):897.
   PubMedGoogle Scholar
• Vlaar APJ, de Bruin S, Busch M, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;2(12): e764–e773.
   PubMedGoogle Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2021. mAbs. 2021;13(1). DOI:10.1080/19420862.2020.1860476
   PubMed Web of Science ®Google Scholar
• Bauer M, Weyland A, Marx G, et al. Efficacy and safety of vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe sepsis or septic shock-A randomized, placebo-controlled, double-blind, multicenter, phase IIa trial (SCIENS study). Critic Care Explorat. 2021;3(11):e0577.
   PubMedGoogle Scholar
• Vlaar APJ, Lim EHT, de Bruin S, et al. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clin Transl Sci. 2022 Jan;15(4):854–858.
   PubMed Web of Science ®Google Scholar
• Jiao X, Wang M, Zhang Z, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021;23(1):11.
   PubMed Web of Science ®Google Scholar
• Yang B, Fulcher JA, Ahn J, et al. Clinical characteristics and outcomes of coronavirus disease 2019 patients who received compassionate-use leronlimab. Clinl Infect Dis. 2020;90095(August):1–8.
   Google Scholar
• Bjork S, Minkin R. Leronlimab and the role of CCR5 supression in covid-19 treatment. Chest. 2021;160(4):A452–A452.
   Web of Science ®Google Scholar
• Yang B, Fulcher JA, Ahn J, et al. Clinical characteristics and outcomes of coronavirus disease 2019 patients who received compassionate-use leronlimab. Clin Infect Dis. 2021;73(11):e4082–e4089.
   PubMed Web of Science ®Google Scholar
• Agresti N, Lalezari JP, Amodeo PP, et al. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab. J Trans Autoimmun. 2021;4:100083. DOI:10.1016/j.jtauto.2021.100083
   PubMedGoogle Scholar
• Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324(2):131–132.
   PubMed Web of Science ®Google Scholar
• Deb P, Molla MMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health. 2021;3(2):87–91.
   PubMedGoogle Scholar